Urinary incontinence may be a common problem among young women who have never been pregnant, according to a study in the Annals of Internal Medicine.
Urinary incontinence may be a common problem among young women who have never been pregnant, according to a study in the Annals of Internal Medicine (2012; 157:I-36).
Researchers from Monash University, Melbourne, Australia conducted a survey of Australian women between the ages of 16 and 30 years who had never been pregnant to investigate the rate of urinary incontinence, its potential risk factors, and effect on quality of life. Women were recruited at six medical clinics in diverse geographic locations, two allied health clinics, and three university campuses. Researchers reviewed 1,002 questionnaires and found that 12.6% reported urinary incontinence.
Women who reported having ever been sexually active and who were not currently using oral contraceptives had the highest rate of urinary incontinence. Young women experiencing urinary incontinence had an increased sense of shame and fear of humiliation. More than one-third of the women with incontinence at least sometimes wore pads to keep dry. They also reported worrying about leakage and body odor, suggesting that incontinence has adverse effects on behavior and psychological well-being for young women.
In contrast to previous studies, the researchers did not find an association between incontinence and age, body mass index, physical activity, or past urinary tract infections.
Go back to this issue of Urology Times eNews.
Related Content
Mid-urethral sling reduces incontinence after prolapse surgery
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.